Physician profile
Justin A Lindsey
NPI 1871014423
$1,387.65
in general payments reported to CMS, 2019-2025
24 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2022: $38.74 · 2023: $77.44 · 2024: $412 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.18 | 2024-2025 | |
| Novo Nordisk INC | $162.55 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.14 | 2024-2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.60 | 2019 | |
| Dexcom, INC. | $75.54 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $70.65 | 2022-2023 | Contrave |
| Lilly USA, LLC | $54.89 | 2024-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $53.07 | 2024 | Watchman Flx |
| Exact Sciences Corporation | $41.81 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $36.60 | 2025 | |
| Irhythm Technologies, INC. | $34.22 | 2024 | Zio Monitor, Zio Xt Patch |
| Rhythm Pharmaceuticals, INC. | $27.30 | 2024 | Imcivree |
| Celgene Corporation | $24.60 | 2019 | |
| Seqirus USA INC | $23.89 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $23.34 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.34 | 2023 | Xarelto |
| Philips North America LLC | $18.79 | 2025 | Extended Holter |
| Collegium Pharmaceutical, INC. | $17.19 | 2025 | Belbuca |
| Abbott Laboratories | $16.71 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.07 | 2019 | |
| Amarin Pharma, INC. | $14.72 | 2019 | |
| Amgen INC. | $14.71 | 2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $14.55 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.